Oppenheimer & Co. Inc. acquired a new stake in shares of Bausch Health Companies Inc (NYSE:BHC) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 14,734 shares of the company’s stock, valued at approximately $378,000.
Several other institutional investors have also recently made changes to their positions in BHC. Tobam bought a new position in Bausch Health Companies during the second quarter worth $13,886,000. Point View Wealth Management Inc. bought a new position in Bausch Health Companies during the second quarter worth $1,132,000. Private Management Group Inc. bought a new position in Bausch Health Companies during the second quarter worth $28,474,000. Van ECK Associates Corp bought a new position in Bausch Health Companies during the second quarter worth $11,494,000. Finally, Marshall Wace LLP bought a new position in Bausch Health Companies during the second quarter worth $2,974,000. Hedge funds and other institutional investors own 42.90% of the company’s stock.
In other news, CFO Paul Herendeen bought 10,000 shares of Bausch Health Companies stock in a transaction dated Friday, September 14th. The shares were bought at an average price of $22.61 per share, for a total transaction of $226,100.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Joseph C. Papa bought 30,000 shares of Bausch Health Companies stock in a transaction dated Friday, September 14th. The stock was purchased at an average price of $22.32 per share, for a total transaction of $669,600.00. The disclosure for this purchase can be found here. Insiders bought a total of 165,000 shares of company stock worth $3,890,700 in the last 90 days. 11.54% of the stock is owned by corporate insiders.
Shares of Bausch Health Companies stock opened at $27.20 on Friday. The firm has a market capitalization of $9.48 billion, a price-to-earnings ratio of 7.10, a price-to-earnings-growth ratio of 0.37 and a beta of -0.28. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.89 and a current ratio of 1.14. Bausch Health Companies Inc has a 52-week low of $13.86 and a 52-week high of $28.45.
Bausch Health Companies (NYSE:BHC) last issued its earnings results on Tuesday, November 6th. The company reported $1.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.84 by $0.31. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The company had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.09 billion. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. Analysts expect that Bausch Health Companies Inc will post 3.7 EPS for the current fiscal year.
Several equities research analysts have issued reports on BHC shares. Zacks Investment Research raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a report on Wednesday, October 3rd. ValuEngine lowered shares of Bausch Health Companies from a “hold” rating to a “sell” rating in a report on Tuesday, October 2nd. TD Securities boosted their price target on shares of Bausch Health Companies from $24.00 to $28.00 and gave the company a “hold” rating in a report on Wednesday. Royal Bank of Canada boosted their price target on shares of Bausch Health Companies from $30.00 to $31.00 and gave the company a “hold” rating in a report on Wednesday. Finally, Mizuho reissued a “buy” rating and issued a $35.00 price target on shares of Bausch Health Companies in a report on Monday, October 8th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $27.55.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/11/10/oppenheimer-co-inc-invests-378000-in-bausch-health-companies-inc-bhc.html.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Featured Article: Asset Allocation and Your Retirement
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.